The safety and immunogenicity of a CETP vaccine in healthy adults
MH Davidson, K Maki, D Umporowicz, A Wheeler… - Atherosclerosis, 2003 - Elsevier
A cholesterol ester transfer protein (CETP) vaccine (CETi-1) that induces auto-antibodies
that specifically bind and inhibit activity of endogenous CETP has been demonstrated in
rabbits to significantly increase HDL-C and reduce the development of atherosclerosis. In a
Phase I human trial with CETi-1, one patient at the highest dose (250 mg) out of a total of 36
patients who received a single injection developed anti-CETP antibodies. In an extension
study of 23 patients, 53%(8/15) who received a second injection of the active vaccine …
that specifically bind and inhibit activity of endogenous CETP has been demonstrated in
rabbits to significantly increase HDL-C and reduce the development of atherosclerosis. In a
Phase I human trial with CETi-1, one patient at the highest dose (250 mg) out of a total of 36
patients who received a single injection developed anti-CETP antibodies. In an extension
study of 23 patients, 53%(8/15) who received a second injection of the active vaccine …
